

BIGFOOT BIOMEDICAL ANNOUNCES NEXT STEP FOR CONNECTED INSULIN INJECTION SYSTEM

Milpitas, CA, Indianapolis, IN. – January 7, 2019 – Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company (NYSE: LLY) to support integration of Lilly’s insulin products into Bigfoot’s systems currently in development.

More than 5 million people in the US who live with type 1 and insulin-requiring type 2 diabetes use injections as their delivery method for insulin therapy, but insulin dosing for glucose management requires a complex set of guidelines, there are few tools to track insulin injection administration, and there is a lack of robust solutions to support healthcare providers in their efforts to implement the prescribed insulin regimens.

“Our agreement with Lilly will enable us to bring Bigfoot’s insulin delivery innovations to the millions of people who trust and rely on Lilly’s insulin products,” said Jeffrey Brewer, Bigfoot Biomedical co-founder and CEO. “We are thrilled to partner with Lilly in our efforts to innovate for people with diabetes and their care teams.”

“Our agreement with Lilly will enable us to bring Bigfoot’s insulin delivery innovations to the millions of people who trust and rely on Lilly’s insulin products.”

Jeffrey Brewer, co-founder and CEO

Bigfoot’s vision is to deliver injection systems as a monthly subscription and bring together insulin dosing support and glucose management with the goal of reducing the daily burden of diabetes management for people with insulin-requiring diabetes. Bigfoot also intends to provide straightforward methods for healthcare providers to review comprehensive data by virtue of a connected service, with the goal of enabling care teams to provide more informed dosing regimens. Bigfoot’s solutions have the potential to improve health outcomes and quality of life for people with diabetes and reduce costs throughout the various healthcare delivery modalities.

The company anticipates a commercial launch of its first two systems, Bigfoot Inject and Bigfoot Loop, in 2020, pending completion of a pivotal clinical trial and subsequent regulatory approvals.

About Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes. With its Loop and Inject systems, the company seeks to reduce the burden of living with insulin-requiring diabetes and to maximize the leverage of health care providers through data, connectivity, automation, and artificial intelligence. Learn more at bigfootbiomedical.com. Follow us on Twitter [@BigfootBiomed](https://twitter.com/BigfootBiomed) and [Facebook](https://www.facebook.com/BigfootBiomed).

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and <http://newsroom.lilly.com/social-channels>.

Media Contacts:

Melissa Lee, Bigfoot Biomedical
mlee@bigfootbiomedical.com, (408) 514-4413

Greg Kueterman, Lilly Media
Kueterman_gregory_andrew@lilly.com, (317) 276-5795